// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Non-tuberculous mycobacterium infection in adult patients: a 10-year single-centre experience

Andrew Pitcher - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Incidence and outcomes of Mycobacterium abscesssus infections in non-Cystic Fibrosis patients

Amirah Valli - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Gastroesophageal reflux disease

N/A

Changing incidence of pneumonia diagnosis in UK primary care from 2002-2017: Population-based cohort study

Xiaohui Sun - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Influenza

N/A

Viral prevalence in stable bronchiectasis: analysis of the Cohort of Asian and Matched European Bronchiectasis (CAMEB)

Kai Xian Thng - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Heparin Binding Protein in sputum compromises epithelial defence and relates to bronchiectasis severity

Alexandria Smith - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Heparin

Risk factors for new P. aeruginosa isolation in bronchiectasis- data from the European Bronchiectasis Registry (EMBARC)

Pierre-Rgis Burgel - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Characterisation of sputum pregnancy zone protein in bronchiectasis

Simon Finch - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Inflammatory molecular endotypes in bronchiectasis

Amelia Shoemark - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis

Irena F Laska - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Cystic Fibrosis

N/A

Neutrophil extracellular traps and the lung microbiome in bronchiectasis

Holly Rachael Keir - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

A point of care neutrophil elastase activity assay identifies bronchiectasis severity, airway infection and risk of exacerbation

Amelia Shoemark - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Elaszym

Determinants of survival in the European Bronchiectasis Registry(EMBARC)

Stefano Aliberti - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Rheumatoid arthritis

N/A

Long term macrolide antibiotics for the treatment of bronchiectasis in adults - individual participant data meta-analysis

Josje Altenburg - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Late Breaking Abstract - The effect of exercise rehabilitation on cardiac function, measured by cardiac MRI, in patients with pre-capillary pulmonary hypertension

Michael McGettrick - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

N/A

Late Breaking Abstract - Supplementation of iron in pulmonary hypertension (SIPHON): results from a randomised controlled crossover trial

Luke Howard - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

Ferric carboxymaltose

Algorithm for pulmonary hypertension screening in sarcoidosis: A Delphi Consensus

Laurent Savale - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Right ventricular dysfunction

N/A

Translation and initial validation of King’s Sarcoidosis Questionnaire

Janne Mller - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Sarcoidosis

N/A

Association of demographic, laboratory and clinical parameters with HRCT-chest findings in patients with sarcoidosis

Stefan Stanel - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Sarcoidosis

N/A

Managing Sarcoidosis in a District General Hospital in Southern England: An 8 year retrospective analysis of treatment

Andrew Achaiah - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Sarcoidosis

N/A

Treatment and management of cardiac sarcoidosis

Juan Carlos Quijano-Campos - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Cardiac sarcoidosis

N/A

Copyright © 2026. QuantiNova All rights reserved